Stock Market Reviews

JAGX (Jaguar Health, Inc.) News

Get the latest news, insights, and market updates on JAGX (Jaguar Health, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Jaguar Health Announces a Special One-time Stock Dividend
  Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced ...
  Feb 18, 2026 - $JAGX
• Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
  Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential ...
  Jan 22, 2026 - $JAGX
• BC-Most Active Stocks
  Tryhard Holdings Ltd. 28,780,305 8.03
  Jan 16, 2026 - $JAGX
• Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
  SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare ...
  Jan 14, 2026 - $JAGX
• Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
  $18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 ...
  Jan 12, 2026 - $JAGX
• Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
  Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associated with significant toxicities to patients, PS has ...
  Jan 6, 2026 - $JAGX
• Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
  SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 ...
  Jan 2, 2026 - $JAGX
• Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
  SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited ...
  Dec 15, 2025 - $JAGX
• FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
  Conditional approval extended through December 2026 for the treatment of CID in dogs CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected SAN FRANCISCO, ...
  Dec 10, 2025 - $JAGX
• Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
  MIAMI, Dec. 09, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com
  Dec 9, 2025 - $JAGX